

Page 2 of 14

Patent

U.S. Appl. No.: 10/031,165 / API-1038-US-PCT

Reply to the Office Action of 28 September 2007

RECEIVED  
CENTRAL FAX CENTER

MAR 28 2008

**Amendment to the Specification:**

Please replace paragraph beginning at line 5 of page 1 with the following amended paragraph:

[0001] This application is a continuation of U.S. application Ser. No. 09/361,619 filed Jul. July 27, 1999, now abandoned.

Please replace paragraph beginning at line 21 of page 39 with the following amended paragraph:

An analysis of the 200 kDa gene (Figure 21) identified three possible sites of matching sequence: GVVK (SEQ ID No: 38) at approximately residue 400; VLGGK (SEQ ID No: 39) at approximately residue 1660; and VVAGK (SEQ ID No: 40) at approximately residue 1820 (see Figure 21). Of these, the first site does not appear in the 3' r200 kDa protein and only a truncation at the third site, the VVAGK (SEQ ID No: 40) sequence, would result in a protein of approximately the observed size.

Please replace paragraph beginning at line 1 of page 40 with the following amended paragraph:

Plasmid pQWF was digested with Dra III and Pst I to remove 1.1 kb of the extreme 3'-end of the 200 kDa gene (Figure 23). A 260 bp PCR fragment was amplified, containing tandem stop codons after the VVAGK (~~SEQ ID No: 51~~) (SEQ ID No: 40) sequence. The PCR primers were designed to contain flanking Dra III and Pst I sites: